C. Preudhomme

发表

p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies

B. Quesnel, E. Wattel, C. Preudhomme, 1994 .

Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression.

B. Quesnel, E. Wattel, C. Preudhomme, 1998, Blood.

Cooperating gene mutations in acute myeloid leukemia: a review of the literature

C. Preudhomme, P. Fenaux, N. Boissel, 2008, Leukemia.

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

D. Birnbaum, E. Solary, W. Vainchenker, 2009, Blood.

Analysis of p16 gene deletion and point mutation in breast carcinoma.

B. Quesnel, J. Bonneterre, J. Peyrat, 1995, British Journal of Cancer.

Mutation in RAP1 is a rare event in myelodysplastic syndromes

C. Preudhomme, C. Lacombe, F. Porteu, 2005, Leukemia.

A 17-gene stemness score for rapid determination of risk in acute leukaemia

Claude Preudhomme, Peter W. Zandstra, Bob Löwenberg, 2016, Nature.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Claude Preudhomme, Robert Barouki, Serge Koscielny, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

Claude Preudhomme, C. Preudhomme, C. Roche-Lestienne, 2003, Seminars in hematology.

Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing

Claude Preudhomme, Mikaël Salson, Mathieu Giraud, 2014, BMC Genomics.

Disease evolution and outcomes in familial AML with germline CEBPA mutations.

J. Gribben, B. Porse, L. Bullinger, 2015, Blood.

MDM2 gene amplification in human breast cancer.

B. Quesnel, J. Peyrat, C. Preudhomme, 1994, European journal of cancer.

Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.

F. Sigaux, A. Baruchel, C. Preudhomme, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.

B. Quesnel, C. Preudhomme, E. Lippert, 2011, Leukemia research.

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

M. Stratton, F. Artiguenave, L. Alexandrov, 2016, Nature Communications.

Activity of elaeochytrin A from Ferula elaeochytris on leukemia cell lines.

B. Quesnel, C. Preudhomme, T. Idziorek, 2008, Phytochemistry.

BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2016, Oncotarget.

Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

A. Duhamel, E. Wattel, C. Preudhomme, 1993, Leukemia.

High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21

E. Macintyre, C. Preudhomme, P. Fenaux, 2000 .

High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.

E. Macintyre, C. Preudhomme, P. Fenaux, 2000, Blood.

Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.

F. Sigaux, J. Soulier, A. Baruchel, 2011, Blood.

Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro

S. Flamant, J. Bourhis, A. Bernheim, 2005, Oncogene.

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

H. Dombret, C. Preudhomme, N. Ifrah, 2015, Haematologica.

Transfer of p16inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation

B. Quesnel, C. Preudhomme, M. Vanrumbeke, 1996, British journal of haematology.

SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL.

H. Dombret, E. Macintyre, C. Preudhomme, 2014, Blood.

SET-NUP 214 is a recurrent gd lineage-speci fi c fusion transcript associated with corticosteroid / chemotherapy resistance in adult TALL

H. Dombret, E. Macintyre, C. Preudhomme, 2014 .

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

D. Steinemann, Alison M. Male, J. Fitzgibbon, 2020, Nature Communications.

Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML

A. Baruchel, R. Favier, H. Raslova, 2019, HemaSphere.

Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia

C. Preudhomme, Y. Bertrand, N. Grardel, 2018, European journal of haematology.

Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France

C. Preudhomme, P. Fenaux, B. Grandbastien, 2001, British journal of haematology.

Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

C. Preudhomme, P. Rousselot, F. Mahon, 2013, Cancer.

Down syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome

A. Baruchel, H. Cavé, A. Verloes, 2017, Haematologica.

Shared clonal IGH rearrangement in BCP‐ALL occurring after CLL: pitfalls and implications for MRD monitoring

C. Preudhomme, J. Marolleau, N. Grardel, 2020, British journal of haematology.

High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis

B. Quesnel, C. Preudhomme, F. Bauters, 2006, Leukemia.

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations

S. Chevret, B. Quesnel, E. Wattel, 2022, British journal of haematology.

Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease

E. Clappier, C. Preudhomme, P. Fenaux, 2021, Leukemia.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients

H. Cavé, P. Rohrlich, E. W. Van Den Neste, 2018, Haematologica.

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes

J. Arnaud, C. Preudhomme, B. Polack, 2017, Oncotarget.

Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia

J. González, F. Sigaux, J. Cayuela, 2015, Oncotarget.

High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients

E. Génin, F. Sigaux, J. Cayuela, 2013, Oncotarget.

Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19

B. Quesnel, S. Susen, C. Preudhomme, 2020, Cancers.

Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r

H. Dombret, C. Preudhomme, R. Itzykson, 2022, bioRxiv.

Rare occurrence of P53 gene mutations in multiple myeloma

C. Preudhomme, P. Fenaux, M. Vanrumbeke, 1992, British journal of haematology.

THE CLINICAL SIGNIFICANCE OF MUTATIONS OF THE P52 TUMOUR SUPPRESSOR GENE IN HAEMATOLOGICAL MALIGNANCIES

C. Preudhomme, P. Fenaux, 1997, British journal of haematology.

Mutations of the P53 gene in acute myeloid leukaemia

R. Berger, C. Preudhomme, P. Fenaux, 1992, British journal of haematology.

The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia

J. Cayuela, A. Baruchel, P. Cony-Makhoul, 2013, Medicine.

Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.

C. Preudhomme, J. Reiffers, V. Praloran, 2006, Haematologica.

Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study

H. Dombret, A. Plesa, C. Preudhomme, 2019, Cancers.

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

P. A. Futreal, J. Dick, M. Minden, 2022, Nature Medicine.

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study.

C. Preudhomme, T. Facon, L. Remontet, 2011, Blood.

TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma.

M. Copin, B. Quesnel, C. Preudhomme, 2002, Annales de genetique.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

H. Dombret, S. Chevret, C. Preudhomme, 2018, Haematologica.

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

C. Flamant, G. Leverger, M. Labopin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Familial myeloid malignancies with germline TET2 mutation

G. Huet, B. Quesnel, C. Preudhomme, 2019, Leukemia.

Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.

B. Quesnel, C. Preudhomme, P. Fenaux, 1994, Leukemia.

Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion

A. Plesa, C. Preudhomme, Y. Bertrand, 2019, HemaSphere.

Acquired trisomy 21 and distinct clonal evolution in acute megakaryoblastic leukaemia in young monozygotic twins

C. Preudhomme, P. Fenaux, R. Zaizov, 2002, British journal of haematology.

Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients

J. Cayuela, P. Cony-Makhoul, C. Preudhomme, 2020, American journal of hematology.

Activity of ladanein on leukemia cell lines and its occurrence in Marrubium vulgare.

B. Quesnel, C. Preudhomme, T. Idziorek, 2010, Planta medica.

Over‐expression of the MDM2 gene is found in some cases of haematological malignancies

B. Quesnel, D. Oscier, C. Preudhomme, 1994, British journal of haematology.

Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature

C. Preudhomme, C. Roumier, C. Roche-Lestienne, 2019, Leukemia & lymphoma.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia

P. Cony-Makhoul, C. Preudhomme, I. Tigaud, 2018, Haematologica.

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis

P. Cony-Makhoul, C. Bastard, C. Preudhomme, 2015, American journal of hematology.

positive chronic eosinophilic leukemia - FIP1L1-PDGFRA responses and achievement of complete molecular remission in Low-dose imatinib mesylate leads to rapid induction of major molecular

M. Rondoni, G. Martinelli, C. Preudhomme, 2013 .

Mutations of PTPN11 are rare in adult myeloid malignancies.

H. Cavé, C. Preudhomme, P. Fenaux, 2005, Haematologica.

Absence of CALR mutations in JAK2-negative polycythemia

C. Preudhomme, V. Ugo, E. Lippert, 2017, Haematologica.

Absence of CALR mutations in JAK 2 negative polycythemia by

C. Preudhomme, E. Lippert, O. Nibourel, 2016 .

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype

H. Dombret, C. Preudhomme, X. Thomas, 2019, Cancers.

Inactivation of the p53 gene in leukemias and myelodysplastic syndrome (MDS) with 17p monosomy.

E. Wattel, C. Preudhomme, P. Fenaux, 1994, Leukemia.

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up.

B. Quesnel, A. Plesa, C. Preudhomme, 2018, Journal of visualized experiments : JoVE.

Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape

F. Jardin, T. Petrella, B. Drénou, 2020, Haematologica.

Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group

J. Bourhis, H. Dombret, B. Quesnel, 2007, Leukemia.

Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation

C. Preudhomme, C. Roumier, N. Milpied, 2002, Leukemia.

Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)

D. Auboeuf, M. Thénoz, E. Wattel, 2015, Oncotarget.

Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias.

E. Gilson, E. Wattel, C. Preudhomme, 2011, Experimental hematology.

Transformation of follicular lymphoma with both t(14;18) and t(8;22).

C. Bastard, C. Preudhomme, P. Duthilleul, 1995, Nouvelle revue francaise d'hematologie.

Restoration of hematopoiesis in a case of myelodysplastic syndrome associated with systemic lupus erythematosus treated with rituximab

C. Preudhomme, J. Villard, C. Chizzolini, 2015, Annals of Hematology.

Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assay

F. Révillion, L. Hornez, J. Peyrat, 1999, Leukemia.

2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.

K. Döhner, M. Heuser, F. Thol, 2021, Blood.

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

M. Heuser, F. Thol, T. Haferlach, 2021 .

The Folate Cycle Enzyme MTHFR is a Critical Regulator of Cell Response to MYC-Targeting Therapies.

K. Stegmaier, J. Qi, H. Dombret, 2019, Cancer discovery.

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

A. Baruchel, H. Cavé, C. Preudhomme, 2010, British journal of haematology.

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents

E. Solary, C. Preudhomme, P. Fenaux, 2018, EBioMedicine.

Linezolid induces ring sideroblasts

B. Quesnel, C. Preudhomme, J. Rossignol, 2013, Haematologica.

17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ.

C. Preudhomme, P. Fenaux, C. Roumier, 1998, Blood.

Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.

E. Wattel, C. Preudhomme, P. Fenaux, 1995, Leukemia.

Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.

C. Preudhomme, P. Fenaux, A. Cosson, 1994, Leukemia.

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.

J. Cayuela, H. Dombret, C. Preudhomme, 2005, Blood.

Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma

C. Preudhomme, C. Maurage, S. Tricot, 2015, British journal of haematology.

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy.

C. Preudhomme, Aline Renneville, C. Rose, 2011, Leukemia research.

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML

E. Clappier, C. Preudhomme, L. Adès, 2022, Blood Cancer Journal.

Mutations of the P53 Gene in Acute Leukemias: A Report on 207 Cases

C. Preudhomme, P. Fenaux, P. Jonveaux, 1994 .

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)

J. Cayuela, C. Preudhomme, M. Tulliez, 2006, Leukemia.

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2013, American journal of hematology.

Response: is there really a relationship between Multidrug Resistance Gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia?

C. Preudhomme, F. Mahon, F. Guilhot, 2010 .

Brief Report Results and Discussion

H. Dombret, C. Bastard, C. Preudhomme, 2022 .

Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.

E. Wattel, C. Preudhomme, P. Fenaux, 1998, Blood.

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

A. Baruchel, C. Preudhomme, H. Sobol, 2009, Blood.

Signatures of Immune Evasion Associated with Blast Transcriptional Leukemia Patients at Diagnosis Are Defective NK Cells in Acute Myeloid

F. Sigaux, J. Cayuela, H. Dombret, 2015 .

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

C. Preudhomme, C. Gardin, P. Rousselot, 2012, Leukemia research.

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.

J. Bourhis, H. Dombret, B. Quesnel, 2011, Blood.

Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia

G. Leverger, M. Labopin, C. Preudhomme, 2010, Leukemia.

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)

C. Preudhomme, P. Fenaux, F. Bauters, 2005, Leukemia.

BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism

B. Quesnel, C. Preudhomme, T. Idziorek, 2008, Leukemia.

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

C. Preudhomme, M. Tulliez, S. Hayette, 2007, Haematologica.

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

B. Quesnel, E. Leprêtre, E. Bertrand, 2014, Clinical Cancer Research.

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

J. Soulier, J. Cayuela, H. Dombret, 2010, Blood.

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia

J. Cayuela, H. Dombret, C. Preudhomme, 2014, Haematologica.

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

H. Dombret, C. Preudhomme, N. Boissel, 2011, Blood.

Improvement of Standardization of Molecular Analyses in Hematology: The 10-year GBMHM French Experience

J. Cayuela, E. Macintyre, C. Preudhomme, 2021, HemaSphere.

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

H. Dombret, B. Quesnel, C. Preudhomme, 2015, Leukemia research.

A certi ﬁ ed plasmid reference material for the standardisation of BCR – ABL1 mRNA quanti ﬁ cation by real-time quantitative PCR

D. Colomer, T. Lion, M. Jansson, 2015 .

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1‐RUNX1T1 fusion quantification on genomic DNA

H. Dombret, C. Preudhomme, Aurélie Caillault, 2014, American journal of hematology.

Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience

J. Cayuela, H. Dombret, E. Macintyre, 2010, Leukemia.

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16)

T. Clozel, C. Preudhomme, P. Fenaux, 2009, Haematologica.

The severity of FIP1L1–PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus

C. Preudhomme, K. Zoi, A. Reiter, 2007, Leukemia.

Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience

H. Dombret, E. Macintyre, T. Fest, 2006, Leukemia.

SNP-array lesions in core binding factor acute myeloid leukemia

H. Dombret, G. Leverger, C. Preudhomme, 2018, Oncotarget.

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

H. Dombret, C. Preudhomme, X. Thomas, 2016 .

Immature platelet fraction (IPF): A reliable tool to predict peripheral thrombocytopenia.

C. Preudhomme, J. Gauthier, V. Soenen, 2019, Current research in translational medicine.

de novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases.

C. Preudhomme, P. Morel, P. Fenaux, 1990, Leukemia research.

A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

A. Stamatoullas, S. Chevret, E. Wattel, 2016, Haematologica.

Paroxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemia—an unusual association: another cause of cytopenia in PNH

M. Copin, C. Preudhomme, C. Roumier, 2015, Annals of Hematology.

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias

D. Birnbaum, E. Solary, O. Bernard, 2013, Leukemia.

Prognostic value of c-mpl expression in myelodysplastic syndromes.

C. Preudhomme, P. Fenaux, V. Ribrag, 1995, Leukemia.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

C. Preudhomme, P. Fenaux, M. Sébert, 2014, Leukemia research.

bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis.

C. Preudhomme, P. Fenaux, A. Cosson, 1995, Leukemia.

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia

C. Preudhomme, P. Rousselot, F. Mahon, 2011, Leukemia.

Is apoptosis a massive process in myelodysplastic syndromes?

C. Preudhomme, P. Fenaux, N. Grardel, 1996, British journal of haematology.

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients

N. Mounier, C. Preudhomme, G. Robert, 2012, Oncotarget.

Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia

H. Dombret, H. Tilly, C. Bastard, 2005, Bone Marrow Transplantation.

Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders

E. Wattel, C. Preudhomme, P. Fenaux, 1997, British journal of haematology.

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia.

G. Huet, B. Quesnel, C. Preudhomme, 2019, Blood.

CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells

B. Quesnel, C. Preudhomme, C. Berthon, 2019, Cancer medicine.

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

J. Soulier, E. Clappier, H. Dombret, 2018, Leukemia.

Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation

C. Preudhomme, X. Thomas, Y. Bertrand, 2009, Leukemia.

5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies

A. Palumbo, H. Dombret, B. Quesnel, 2014 .

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine

B. Quesnel, A. Duhamel, C. Preudhomme, 2016, Leukemia.

The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy

Anna L. Brown, S. Fröhling, G. Natsoulis, 2021, Haematologica.

Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults

C. Preudhomme, C. Berthon, Emma Lachaier, 2021, HemaSphere.

Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial.

G. Leverger, T. Leblanc, C. Preudhomme, 2020, Haematologica.

Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders

P. Nurden, G. Leverger, R. Favier, 2016, Orphanet Journal of Rare Diseases.

del(17p) in myeloid malignancies

C. Preudhomme, P. Fenaux, M. Zandecki, 2011 .

Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS

B. Quesnel, C. Preudhomme, P. Fenaux, 2010 .

A multiparametric niche-like drug screening platform in acute myeloid leukemia

E. Clappier, H. Dombret, C. Preudhomme, 2022, Blood Cancer Journal.

Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations

H. Dombret, C. Preudhomme, M. Cheok, 2015, American journal of hematology/oncology.

Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia

H. Dombret, C. Preudhomme, M. Cheok, 2015 .

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

H. Dombret, A. Plesa, C. Preudhomme, 2016, Blood.

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

H. Dombret, R. Hills, C. Preudhomme, 2015 .

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial.

H. Dombret, C. Preudhomme, X. Thomas, 2019, Blood.

Minimal Residual Disease Assessed by WT1 Expression and NPM1 Mutations Specific RQ-PCR Assays Identifies Patients with Distinct Outcomes in the ALFA 0701 Trial and Is Decreased by Treatment with Gemtuzumab Ozogamicin

J. Cayuela, H. Dombret, C. Preudhomme, 2012 .

Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML

B. Quesnel, I. Yakoub-Agha, A. Duhamel, 2017, Bone Marrow Transplantation.

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial.

J. Bourhis, H. Dombret, B. Quesnel, 2012, Leukemia research.

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group

L. Miguet, A. Plesa, C. Preudhomme, 2022, Leukemia.

Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease

E. Clappier, C. Preudhomme, P. Fenaux, 2021, Leukemia.

MDS/CMML with TET2 or IDH mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation

E. Clappier, C. Preudhomme, P. Fenaux, 2020 .

Very low incidence of p53 antibodies in adult non‐Hodgkin's lymphoma and multiple myeloma

T. Soussi, C. Preudhomme, P. Fenaux, 1998, British journal of haematology.

The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases.

B. Quesnel, C. Preudhomme, P. Fenaux, 1995, Leukemia & lymphoma.

Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis.

C. Preudhomme, P. Morel, P. Fenaux, 1992, Leukemia.

Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases.

R. Berger, C. Preudhomme, P. Fenaux, 1992, Leukemia.

The role of intensive chemotherapy in myelodysplastic syndromes.

C. Preudhomme, P. Fenaux, M. Hebbar, 1992, Leukemia & lymphoma.

Clinics and pathology Disease Acute non lymphocytic leuemia / myelodysplastic syndromes

C. Preudhomme, P. Fenaux, M. Zandecki, 2011 .

Good predictive value of combined cytogenetic and molecular follow up in chronic myelogenous leukemia after non T-cell depleted allogeneic bone marrow transplantation: a report on 38 consecutive cases.

E. Wattel, C. Preudhomme, P. Fenaux, 1995, Leukemia & lymphoma.

Cases With 17p Deletion Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Acute Myeloid Leukemia and Myelodysplastic Syndromes Following

C. Preudhomme, P. Fenaux, Y. Sterkers, 2013 .

Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.

C. Preudhomme, P. Fenaux, N. Grardel, 1998, Leukemia & lymphoma.

Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.

E. Wattel, C. Preudhomme, P. Fenaux, 1998, Blood.

p 16 Gene Homozygous Deletions in Acute Lymphoblastic Leukemia

B. Quesnel, E. Wattel, C. Preudhomme, 2002 .

Gene Homozygous Deletions in Acute Lymphoblastic Leukemia

B. Quesnel, E. Wattel, C. Preudhomme, 2002 .

A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia

C. Preudhomme, Aurélie Caillault, S. Geffroy, 2018, Haematologica.

Neurofibromatosis‐1 gene deletions and mutations in de novo adult acute myeloid leukemia

J. Soulier, H. Dombret, C. Preudhomme, 2013, American journal of hematology.

e- Blood Myelodysplasia and leukemia of Fanconi anemia are associated with a speciﬁc pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions

F. Sigaux, J. Soulier, A. Baruchel, 2011 .

Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients

C. Preudhomme, P. Fenaux, Aline Renneville, 2006, Leukemia.

Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?

C. Preudhomme, P. Fenaux, S. de Botton, 2002, Blood.

Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes

B. Quesnel, C. Preudhomme, P. Fenaux, 1994, British journal of haematology.

p16ink4a gene and hematological malignancies.

B. Quesnel, C. Preudhomme, P. Fenaux, 1996, Leukemia & lymphoma.

p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?

C. Preudhomme, P. Fenaux, C. Roumier, 1999, Haematologica.

Differential efficacy of adenoviral mediated gene transfer into cells from hematological cell lines and fresh hematological malignancies.

H. Haddada, E. Wattel, C. Preudhomme, 1996, Leukemia.

Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia.

R. Lubin, C. Preudhomme, P. Fenaux, 1994, Leukemia.

Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes.

B. Quesnel, C. Preudhomme, P. Fenaux, 1993, Leukemia.

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.

H. Dombret, C. Preudhomme, T. Cluzeau, 2021, Blood.

Persistence of AML1/ETO fusion mRNA in t(8;21) acute myeloid leukemia (AML) in prolonged remission: is there a consensus?

E. Macintyre, C. Preudhomme, P. Fenaux, 1996, Leukemia.

Quantification of JAK2V617F mutation by next‐generation sequencing technology

C. Preudhomme, E. Lippert, Aline Renneville, 2013, American journal of hematology.

Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine

C. Preudhomme, P. Fenaux, L. Adès, 2012 .

Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease

B. Quesnel, C. Preudhomme, P. Fenaux, 2000, Gene Therapy.

Combined immunophenotyping and in situ hybridization (FICTION): a rapid method to study cell lineage involvement in myelodysplastic syndromes

C. Preudhomme, P. Fenaux, A. Cosson, 1995, British journal of haematology.

Is translocation (8;21) a "favorable" cytogenetic rearrangement in acute myeloid leukemia?

C. Preudhomme, P. Fenaux, F. Bauters, 1990, Nouvelle revue francaise d'hematologie.

Immunoglobulin and T-cell receptor delta gene rearrangements are rarely found in myelodysplastic syndromes in chronic phase.

C. Preudhomme, P. Fenaux, A. Cosson, 1994, Leukemia research.

T-cell acute lymphoblastic leukemia occurring in the course of B cell chronic lymphocytic leukemia: a case report.

C. Preudhomme, P. Fenaux, M. Zandecki, 1995, Leukemia & lymphoma.

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

A. Stamatoullas, S. Chevret, E. Wattel, 2019, Haematologica.

Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes.

B. Quesnel, E. Wattel, C. Preudhomme, 1993, Leukemia.

Immunological detection of myeloperoxidase in poorly differentiated acute leukemia

C. Preudhomme, P. Fenaux, A. Cosson, 1993, European journal of haematology.

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML

I. Yakoub-Agha, C. Preudhomme, T. Facon, 2005, Leukemia.

Origines de la résistance au traitement par imatinib mésylate : Un exemple riche d’enseignements

C. Preudhomme, F. Mahon, C. Roche-Lestienne, 2004 .

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

C. Preudhomme, I. Tigaud, J. Laï, 2007, Blood.

Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.

C. Preudhomme, P. Rousselot, F. Mahon, 2005 .

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

A. Vekhoff, C. Preudhomme, V. Eclache, 2008 .

P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q

C. Preudhomme, P. Fenaux, T. Cluzeau, 2013 .

FISH analysis with a YAC probe improves detection of LAZ3/BCL6 rearrangement in non-Hodgkin's lymphoma.

C. Bastard, C. Preudhomme, P. Fenaux, 2000, The hematology journal : the official journal of the European Haematology Association.

Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)

C. Preudhomme, P. Fenaux, M. Vanrumbeke, 1997, Leukemia.

Acute myeloid leukemia with translocation t(3;5): new molecular insights

C. Preudhomme, Aline Renneville, O. Nibourel, 2013, Haematologica.

Acute myeloid leukemia with translocation t ( 3 ; 5 ) : new molecular insight by

C. Preudhomme, Aline Renneville, O. Nibourel, 2013 .

Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC)

A. Vekhoff, C. Preudhomme, P. Rousselot, 2012 .

Investigation of minimal residual disease in adult Ph1 positive acute lymphoblastic leukemia by a combination of cell sorting and fluorescence in situ hybridization: a preliminary study on 6 cases.

C. Preudhomme, P. Fenaux, J. Laï, 2000, Haematologica.

C6) Mutations of the P53 gene in myelodysplastic syndromes (MDS). A report on 152 cases

R. Berger, C. Preudhomme, P. Fenaux, 1991 .

Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström’s macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2017, Oncotarget.

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

H. Dombret, S. Chevret, C. Preudhomme, 2011 .

Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study.

J. Bourhis, H. Dombret, S. Chevret, 2007 .

A new murine aggressive leukemic model.

B. Quesnel, C. Preudhomme, P. Fenaux, 1999, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

B7‐H3 protein expression in acute myeloid leukemia

B. Quesnel, C. Preudhomme, C. Berthon, 2015, Cancer medicine.

Absence of rearrangement of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes and acute myeloid leukemia.

B. Quesnel, C. Preudhomme, P. Fenaux, 1994, Leukemia.

Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype

B. Quesnel, C. Preudhomme, P. Fenaux, 2001, Leukemia.

An Association Between the Common Hereditary Hemochromatosis Mutation and the Factor V Leiden Allele in a Population With Thrombosis

C. Preudhomme, P. Fenaux, Y. Sterkers, 1998 .

Absence of germline mutations of exons 5 to 8 of the P53 gene in 26 breast cancer families from the north of France.

J. Bonneterre, C. Preudhomme, P. Fenaux, 1993, European journal of cancer.

Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay

C. Preudhomme, P. Fenaux, C. Roumier, 1999, Leukemia.

Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients

E. Wattel, C. Preudhomme, F. Bauters, 1993, British journal of haematology.

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders

C. Preudhomme, Aline Renneville, C. Rose, 2008, Leukemia.

Absence of BCR-ABL rearrangement (with m-bcr breakpoint) in chronic myelomonocytic leukemia.

C. Preudhomme, P. Fenaux, M. Vanrumbeke, 1994, Leukemia.

Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis.

B. Quesnel, C. Preudhomme, E. Cornet, 2012, Leukemia research.

LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.

E. Macintyre, F. Garnache-Ottou, C. Preudhomme, 2016, Blood.

O7.3BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies

A. Palumbo, H. Dombret, P. Hérait, 2015 .

High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.

C. Preudhomme, Aurélie Caillault, Mikaël Salson, 2017, Leukemia research.

Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia

H. Dombret, A. Baruchel, F. Lacombe, 2019, Leukemia.

Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia

H. Dombret, A. Baruchel, F. Lacombe, 2018, Hematological oncology.

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells

B. Quesnel, C. Preudhomme, T. Idziorek, 2011, Oncogene.

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

J. Cayuela, H. Dombret, S. Chevret, 2014, Oncotarget.

Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use

H. Dombret, C. Preudhomme, S. de Botton, 2020, Haematologica.

The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication.

H. Dombret, C. Preudhomme, C. Gardin, 2009, Blood.

Recurrent in-frame insertion in C/EBPα TAD2 region is a polymorphism without prognostic value in AML

P. Amouyel, H. Dombret, D. Cottel, 2008, Leukemia.

Cytogénétique Hématologique (GFCH) d'Hématologie Cellulaire (GFHC) and the Groupe Français de gene mutations: a report of 59 cases by the Groupe Français M0 AML, clinical and biologic features of the disease, includingAML1

O. Casasnovas, E. Macintyre, R. Berger, 2013 .

Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1–PRDM16 fusion in a case of progressive chronic myeloid leukemia: A complex chromosomal rearrangement of underestimated frequency in disease progression?

C. Preudhomme, J. Laï, C. Roche-Lestienne, 2008, Genes, chromosomes & cancer.

Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia

M. Lübbert, C. Preudhomme, P. Fenaux, 2003, Leukemia.

Brief report M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Franc¸ais d’He´matologie Cellulaire (GFHC) and the Groupe Franc¸ais de Cytoge´ne´tique He´matologique (GFCH)

O. Casasnovas, E. Macintyre, R. Berger, 2003 .

ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia

H. Cavé, C. Preudhomme, B. Grandchamp, 1997, Leukemia.

NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors

E. Clappier, C. Preudhomme, N. Grardel, 2016, Haematologica.

Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies

A. Palumbo, H. Dombret, B. Quesnel, 2014 .

Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group

A. Baruchel, G. Leverger, M. Labopin, 2018, HemaSphere.

The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories

A. Kohlmann, T. Haferlach, S. Chiaretti, 2012 .

The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group

J. Downing, S. Shurtleff, J. D. Vos, 2008 .

Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML)

E. Solary, W. Vainchenker, O. Bernard, 2012 .

Which AML Subsets Benefit from Leukemic Cell Priming during Chemotherapy? Long-Term Analysis of the ALFA-9802 GM-CSF Study

J. Bourhis, H. Dombret, C. Preudhomme, 2008 .

Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies

E. Clappier, H. Cavé, C. Preudhomme, 2009, Leukemia.

Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

B. Quesnel, E. Wattel, C. Preudhomme, 1993, Leukemia.

Philadelphia negative, BCR-ABL positive adult acute lymphoblastic leukemia (ALL) in 2 of 39 patients with combined cytogenetic and molecular analysis.

C. Preudhomme, P. Fenaux, M. Zandecki, 1993, Leukemia.

99 Expression of LRP and its correlation with other drug resistance proteins and outcome in myelodysplastic syndromes (MDS)

E. Wattel, C. Preudhomme, P. Fenaux, 1997 .

Presence of inv (16) May Be One of the Only “Favorable” Prognostic Factors in AML: A Report on 16 Cases

C. Preudhomme, P. Fenaux, F. Bauters, 1994 .

Real-time quantitative PCR (RQ-PCR) detection of minimal residual disease (MRD) by optimized WT1 assay to enhance risk stratification in acute myeloid leukemia (AML): A European leukemia net study [Abstract]

R. Hills, S. Schnittger, C. Preudhomme, 2007 .

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

S. Broutin, J. Delahousse, A. Paci, 2018, Leukemia.

Final Analysis of the ALFA 0701 Study

H. Dombret, S. Chevret, C. Preudhomme, 2014 .

Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia

O. Abdel-Wahab, R. Favier, H. Raslova, 2016, Leukemia.

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

A. Vekhoff, E. Solary, C. Preudhomme, 2011, Blood.

BRIEF COMMUNICATION Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)

C. Preudhomme, P. Fenaux, M. Vanrumbeke, 1997 .

Frequency of molecular elimination of Ph1 clone in chronic myelogenous leukemia (CML) with interferon alpha.

C. Preudhomme, P. Fenaux, M. Simon, 1996, Leukemia.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

O. Abdel-Wahab, H. Dombret, G. Leverger, 2016, Blood.

Cytogenetically masked CBFB-MYH11 fusion and concomitant TP53 deletion in a case of acute myeloid leukemia with a complex karyotype

C. Preudhomme, I. Luquet, C. Terré, 2020, Leukemia & lymphoma.

Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study.

H. Dombret, H. Tilly, S. Chevret, 2004, Blood.

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)

H. Dombret, A. Baruchel, G. Leverger, 2006, Leukemia.

Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia.

C. Preudhomme, Aurélie Caillault, C. Berthon, 2020, Blood.

A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.

J. Bourhis, H. Dombret, S. Chevret, 2020, Blood.

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.

J. Bourhis, H. Dombret, C. Preudhomme, 2020, Blood advances.

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412)

H. Dombret, S. Chevret, C. Preudhomme, 2015 .

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

H. Dombret, S. Leprêtre, P. Chevallier, 2015, Haematologica.

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

J. Cayuela, H. Dombret, S. Chevret, 2013, Blood.

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

H. Dombret, S. Chevret, B. Quesnel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

H. Dombret, S. Chevret, C. Preudhomme, 2012, The Lancet.

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.

J. Bourhis, H. Dombret, S. Chevret, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Torsten Haferlach, Claude Preudhomme, Wolfgang Kern, 2018, Blood.

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

H. Dombret, C. Preudhomme, N. Boissel, 2020, International journal of molecular sciences.

The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia

Stanley W. K. Ng, J. Dick, A. Baruchel, 2018, Leukemia.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

J. Cayuela, H. Dombret, C. Preudhomme, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

V. V. D. van der Velden, R. Hills, S. Schnittger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Which AML subsets benefit from leukemic cell priming during chemotherapy? Long‐term analysis of the ALFA‐9802 GM‐CSF study

H. Dombret, C. Preudhomme, C. Gardin, 2010, Cancer.

Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists

C. Preudhomme, Aline Renneville, S. Lejeune, 2016, Expert review of hematology.

Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.

E. Wattel, C. Preudhomme, P. Fenaux, 1998, Blood.

A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia

C. Preudhomme, M. Cheok, N. Duployez, 2018, Oncotarget.

Humulane and germacrane sesquiterpenes from Ferula lycia.

B. Quesnel, C. Preudhomme, T. Idziorek, 2010, Journal of natural products.

Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors

C. Preudhomme, C. Willekens, E. Boudry-Labis, 2015, Expert review of hematology.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association

H. Dombret, C. Preudhomme, P. Fenaux, 2011, Leukemia.

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

H. Dombret, B. Quesnel, C. Preudhomme, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia

H. Dombret, C. Preudhomme, X. Thomas, 2009, Cancer.

CEBPA point mutations in hematological malignancies

C. Preudhomme, P. Fenaux, C. Roumier, 2005, Leukemia.

New mechanisms of AML1 gene alteration in hematological malignancies

C. Preudhomme, P. Fenaux, V. Eclache, 2003, Leukemia.

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).

J. Cayuela, H. Dombret, C. Preudhomme, 2002, Blood.

C. Preudhomme, P. Fenaux, Y. Sterkers, 1999, Leukemia.

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.

B. Quesnel, E. Wattel, C. Preudhomme, 1994, Blood.

Copy-number analysis identified new prognostic marker in acute myeloid leukemia

J. Soulier, H. Dombret, B. Quesnel, 2017, Leukemia.

Outcome of older patients with acute myeloid leukemia in first relapse

H. Dombret, S. Chevret, B. Quesnel, 2013, American journal of hematology.

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia

X Thomas, H. Dombret, C. Preudhomme, 2011, Leukemia.

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

H. Dombret, J. Bibault, C. Preudhomme, 2015, Oncotarget.

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in AML

P. A. Futreal, J. Dick, M. Minden, 2022, bioRxiv.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

H. Dombret, B. Quesnel, P. Hérait, 2016, The Lancet. Haematology.

Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951.

F. Speleman, A. Hagemeijer, H. Cavé, 2004, Blood.

NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951

F. Speleman, E. Clappier, H. Cavé, 2010, Leukemia.

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively

C. Preudhomme, X. Thomas, S. Hayette, 2021, Cancers.

Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy

X Thomas, F. Sigaux, J. Cayuela, 2002, Leukemia.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Claude Preudhomme, Daniel Birnbaum, Olivier Kosmider, 2012, Blood.

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study.

H. Dombret, C. Preudhomme, L. Adès, 2021, Blood.

Chromosomal insertion involving MLL in childhood acute myeloblastic leukemia (M4).

C. Preudhomme, J. Andrieux, J. Laï, 2004, Cancer genetics and cytogenetics.

p16 gene homozygous deletions in acute lymphoblastic leukemia.

B. Quesnel, E. Wattel, C. Preudhomme, 1995, Blood.

ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia

Eunhee Kim, Claude Preudhomme, Alessandro Pastore, 2017, Nature Communications.

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

O. Abdel-Wahab, H. Dombret, G. Leverger, 2014, Blood.

Frequent ASXL 2 mutations in acute myeloid leukemia patients with t ( 8 ; 21 ) / RUNX 1-RUNX 1 T 1 chromosomal translocations

O. Abdel-Wahab, H. Dombret, G. Leverger, 2014 .

MOZ is fused to p300 in an acute monocytic leukemia with t(8;22)

D. Birnbaum, C. Preudhomme, M. Pébusque, 2000, Genes, chromosomes & cancer.

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Claude Preudhomme, Pierre Fenaux, C. Preudhomme, 2002, Blood.

Diagnosis, classification, and cytogenetics of myelodysplastic syndromes.

C. Mecucci, C. Preudhomme, P. Fenaux, 1998, Haematologica.

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

D. Maucort-Boulch, D. Auboeuf, E. Wattel, 2017, Leukemia research.

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

B. Quesnel, C. Preudhomme, P. Fenaux, 2011, Leukemia.

Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignancies.

C. Béroud, I. Soubeyran, L. Miguet, 2021, European journal of cancer.

Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma

C. Preudhomme, P. Fenaux, F. Bauters, 2000, Oncogene.

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

C. Preudhomme, T. Facon, J. Laï, 2003, The New England journal of medicine.

Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia

A. Baruchel, G. Leverger, E. Macintyre, 2018, Leukemia.

Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications

C. Preudhomme, M. Cheok, F. Gonzales, 2021, Expert opinion on therapeutic targets.

Genomic structure and assignment of the RhoH/TTF small GTPase gene (ARHH) to 4p13 by in situ hybridization.

C. Preudhomme, C. Roumier, S. Galiègue‐Zouitina, 1997, Genomics.

Therapy in Newly Diagnosed Acute Promyelocytic Leukemia Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by

J. Miguel, H. Dombret, A. Stamatoullas, 2014 .

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.

J. Miguel, H. Dombret, A. Stamatoullas, 2000 .

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial

H. Dombret, A. Stamatoullas, E. Solary, 2000, British journal of haematology.

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

J. Miguel, H. Dombret, A. Stamatoullas, 1999, Blood.

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics

B. Quesnel, C. Preudhomme, P. Fenaux, 2005, Leukemia.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

M. Rondoni, G. Martinelli, C. Preudhomme, 2007, Blood.

Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft

C. Preudhomme, C. Rose, E. Bourgeois, 2004, Leukemia.

A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis

E. Laurenti, H. Dombret, E. Macintyre, 2019, bioRxiv.

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.

J. Soulier, J. Cayuela, A. Baruchel, 2018, Blood.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

A. Stamatoullas, P. Cony-Makhoul, S. Chevret, 2016, Leukemia.

Lenalidomide with or without Erythropoietin in transfusion dependent erythropoiesis-stimulating agent-refractory lower risk MDS without 5 q deletion Running title : Lenalidomide in transfused non del 5 q low risk MDS

Stanislas, Taksin, A. Stamatoullas, 2015 .

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

H. Dombret, C. Preudhomme, X. Thomas, 2018, Haematologica.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

H. Dombret, B. Quesnel, C. Preudhomme, 2015, Oncotarget.

Acute myeloblastic leukemia (AML) with inv (16)(p13;q22) and the rare I type CBFβ-MYH11 transcript: report of two new cases

C. Preudhomme, P. Fenaux, C. Roumier, 2002, Leukemia.

PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study

J. D. Vos, P. Brousset, J. Soulier, 2009, Leukemia.

The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?

C. Preudhomme, F. Nicolini, Q. Le, 2007, Leukemia.

Genome-wide association study identi ﬁ es susceptibility loci for acute myeloid leukemia

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, C. Gieger, 2022 .

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR–JAK2 fusion transcript

C. Preudhomme, C. Berthon, O. Nibourel, 2016, European journal of haematology.

AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML.

T. Lister, A. Rohatiner, C. Preudhomme, 2006, Blood.

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

D. Steinemann, Alison M. Male, J. Fitzgibbon, 2020, Nature Communications.

Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival

J. Fitzgibbon, J. Cavenagh, C. Preudhomme, 2012, Haematologica.

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

C. Preudhomme, Aline Renneville, J. Laï, 2008, Genes, chromosomes & cancer.

Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases.

C. Preudhomme, P. Fenaux, C. Roumier, 2005, Cancer genetics and cytogenetics.

Involvement of peripheral blood cells in multiple myeloma: chromosome changes are the rule within circulating plasma cells but not within B lymphocytes.

C. Preudhomme, F. Bauters, T. Facon, 1997, Leukemia.

C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.

S. Bohlander, D. Tenen, J. A. Pulikkan, 2010, Blood.

Significance of circulating plasma cells in multiple myeloma.

C. Preudhomme, F. Bauters, T. Facon, 1994, Leukemia & lymphoma.

Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.

P. Laurent-Puig, J. Peyrat, T. Soussi, 1993, Cancer research.

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

B. Quesnel, E. Bertrand, C. Preudhomme, 2012, Blood.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Claude Preudhomme, Philippe Rousselot, A. Vekhoff, 2010, The New England journal of medicine.

Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias

C. Preudhomme, L. Garçon, I. Luquet, 2021, Genes, chromosomes & cancer.

Multi‐loci diagnosis of acute lymphoblastic leukaemia with high‐throughput sequencing and bioinformatics analysis

Claude Preudhomme, Mikaël Salson, Mathieu Giraud, 2016, British journal of haematology.

CD3−CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder

G. Salles, M. Copin, C. Preudhomme, 2015, Haematologica.

IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner

C. Preudhomme, V. Asnafi, K. Beldjord, 2005, Leukemia.

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Martin C. Müller, I. Dufva, G. Martinelli, 2009, Blood.

Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?

H. Dombret, C. Preudhomme, N. Boissel, 2009, Current opinion in hematology.

Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules

C. Preudhomme, F. Mahon, F. Guilhot, 2015, Cancer.

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

H Emons, V Kairisto, S Trapmann, 2014, Leukemia.

Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale.

J. Cayuela, C. Preudhomme, O. Nibourel, 2014, Clinical Biochemistry.

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.

A. Stamatoullas, E. Solary, S. Chevret, 2016, Blood.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

D. Birnbaum, T. Haferlach, E. Solary, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.

A. Stamatoullas, C. Bastard, C. Preudhomme, 2012 .

RNA for reverse PCR analysis can be obtained from bone marrow cells prepared for cytogenetic analysis and stored at -20 degrees C for several years.

C. Preudhomme, P. Fenaux, J. Lai, 1995, Leukemia.

Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia

S. Susen, B. Jude, C. Preudhomme, 2016, Haematologica.

Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies

S. Susen, C. Preudhomme, C. Berthon, 2020, British journal of haematology.

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

D. Birnbaum, S. Miyano, Y. Shiraishi, 2013, Blood.

Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML

H. Dombret, B. Quesnel, C. Preudhomme, 2021, Leukemia.

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

C. Preudhomme, T. Facon, J. Laï, 2005, Haematologica.

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.

H. Dombret, T. Haferlach, G. Leverger, 2018, Blood.

Expression of the multidrug resistance‐associated protein in myelodysplastic syndromes

E. Wattel, C. Preudhomme, P. Fenaux, 2000, British journal of haematology.

Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study

H. Dombret, A. Delannoy, J. Gabert, 2006, Leukemia.

Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases

R. Beuscart, C. Preudhomme, P. Morel, 1989, British journal of haematology.

Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML

H. Dombret, C. Preudhomme, P. Fenaux, 2012, Bone Marrow Transplantation.

Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia

E. Clappier, L. Faivre, C. Preudhomme, 2020 .

Clonal architecture of chronic myelomonocytic leukemias.

E. Solary, W. Vainchenker, O. Bernard, 2013, Blood.

Correction: Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Patricia Marino, Rajae Touzani, Lionel Perrier, 2018, European Journal of Human Genetics.

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Dede Sika Kossi, On behalf of NGSEco Group, I. Durand-zaleski, 2017, European Journal of Human Genetics.

Partial duplication of the MLL oncogene in patients with aggressive acute myeloid leukemia.

C. Mecucci, M. Martelli, C. Preudhomme, 2004, Haematologica.

Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow.

H. Dombret, E. Macintyre, G. Vassiliou, 2020, Cell reports.

CYTOGENETIC AND MOLECULAR REMISSION IN A CASE OF ACUTE MYELOID LEUKAEMIA (AML) WITH INVERSION OF CHROMOSOME 16 (Inv(16)) AND PHILADELPHIA CHROMOSOME (Ph)

C. Preudhomme, P. Fenaux, M. Zandecki, 1992, British journal of haematology.

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study

F. Pasquier, E. Clappier, S. Broutin, 2020, Leukemia & lymphoma.

Familial CEBPA-mutated acute myeloid leukemia.

J. Fitzgibbon, C. Preudhomme, A. Rio-Machin, 2017, Seminars in hematology.

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

H. Dombret, B. Quesnel, P. Hérait, 2014 .

Analysis of p 53 Antibodies in Patients with Various Cancers Define B-Cell Epitopes of Human p 53 : Distribution on Primary Structure and Exposure on Protein Surface 1

P. Laurent-Puig, J. Peyrat, T. Soussi, 2006 .

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

E. Estey, G. Lenz, H. Dombret, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.

J. Soulier, E. Clappier, H. Dombret, 2022, Blood.

Genetic Identification of AML Patients Older than 60 years Achieving Long-term Survival with Intensive Chemotherapy.

H. Dombret, C. Preudhomme, T. Cluzeau, 2021, Blood.

Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature.

H. Dombret, M. Béné, C. Preudhomme, 2020, Blood advances.

ABCA3 Expression Predicts Response to Gemtuzumab Ozogamicin in AML

D. Maucort-Boulch, H. Dombret, E. Wattel, 2016 .

De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features?

E. Wattel, C. Preudhomme, P. Morel, 1993, Leukemia research.

Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.

F. Jardin, J. Colinge, T. Petrella, 2021, Blood advances.

Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study.

J. Cayuela, H. Dombret, A. Vekhoff, 2004 .

Trisomy 8 in the Light of Recent Cytogenetic Classification Advances. A Study From the French Acute Myeloid Leukemia Intergroup.

H. Dombret, C. Preudhomme, E. Lippert, 2009 .

Persistence of Mutations in Complete Remission Including DNMT3A, TET2 and ASXL1 Mutations Is Associated with Worse Prognosis in Patients with Acute Myeloid Leukemia Treated in ALFA 0702 Study

H. Dombret, C. Deswarte, C. Preudhomme, 2022, Blood.

MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome

B. Quesnel, E. Bertrand, C. Preudhomme, 2014, British journal of haematology.

M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH).

O. Casasnovas, E. Macintyre, R. Berger, 2003, Blood.

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2017, Clinical Cancer Research.

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.

J. Bourhis, H. Dombret, C. Preudhomme, 2007, Blood.

Effect of Priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Younger Adults with Newly Diagnosed Acute Myeloid Leukemia (AML): A Trial by the Acute Leukemia French Association (ALFA) Group.

J. Bourhis, H. Dombret, B. Quesnel, 2005 .

Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively

E. Clappier, H. Dombret, A. Plesa, 2022, HemaSphere.

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial

Sylvie Chevret, Claude Preudhomme, Hassan Farhat, 2014, Oncotarget.

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

C. Preudhomme, M. Tulliez, S. Hayette, 2006 .

A Retrospective 20-Year Survey of the Incidence of Chronic Myeloid Leukemia in the Northern France Region.

C. Preudhomme, T. Facon, J. Laï, 2006 .

Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib.

C. Preudhomme, F. Mahon, F. Guilhot, 2014, Leukemia research.

[Molecular abnormalities and clonality in myelodysplastic syndromes].

C. Preudhomme, P. Fenaux, 1997, Pathologie-biologie.

Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.

R. Letestu, C. Preudhomme, P. Fenaux, 2018, Leukemia research.

Incidence and Prognosis of RTKs and RAS Mutations in CBF AML. A Retrospective Study of French Adult ALFA and Pediatric LAME Trials.

H. Dombret, A. Baruchel, T. Leblanc, 2004 .

A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients

Stanley W. K. Ng, L. Bullinger, H. Döhner, 2018, Blood.

Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse

C. Preudhomme, P. Rousselot, Aline Renneville, 2014, American journal of hematology.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

H. Dombret, S. Chevret, C. Preudhomme, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

F. Jardin, T. Petrella, E. Macintyre, 2019, Blood advances.

The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies

F. Jardin, P. Gaulard, G. Salles, 2018, HemaSphere.

Characterisation of Asp669Tyr Piezo1 cation channel activity in red blood cells: an unexpected phenotype

G. Bouyer, C. Preudhomme, C. Rose, 2021, British journal of haematology.

Fluorescence in situ hybridization improves the detection of monosomy 7 in myelodysplastic syndromes.

C. Preudhomme, P. Fenaux, J. Lai, 1994, Leukemia.

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

H. Dombret, C. Preudhomme, L. Adès, 2019, Blood.

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

H. Dombret, C. Preudhomme, C. Gardin, 2021, Blood.

Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines

P. Rohrlich, N. Mounier, C. Preudhomme, 2014, Oncotarget.

Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases.

E. Wattel, C. Preudhomme, B. Hecquet, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation

B. Quesnel, C. Preudhomme, Aline Renneville, 2007, Leukemia.

Real‐life challenges using personalized prognostic scoring systems in acute myeloid leukemia

L. Mannone, C. Preudhomme, G. Robert, 2022, Cancer medicine.

Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients.

C. Preudhomme, P. Fenaux, M. Zandecki, 2008, Clinical and laboratory haematology.

Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study

E. Solary, C. Preudhomme, P. Fenaux, 2020, Leukemia.

Identification of a YAC spanning the translocation breakpoint t(8;22) associated with acute monocytic leukemia

D. Birnbaum, J. Fletcher, C. Preudhomme, 1996, Genes, chromosomes & cancer.

Acute monocytic leukemia with (8;22)(p11;q13) translocation. Involvement of 8p11 as in classical t(8;16)(p11;p13).

C. Preudhomme, P. Fenaux, T. Facon, 1992, Cancer genetics and cytogenetics.

Chromosomal Minimal Critical Regions in Therapy-Related Leukemia Appear Different from Those of De Novo Leukemia by High-Resolution aCGH

J. Bourhis, P. Dessen, C. Richon, 2011, PloS one.

11 Glutathione S transferase theta 1 (GSTT1) gene defects in myelodysplastic syndromes (MDS) and their correlation with Kryotype and exposure to potential carcinogens

C. Preudhomme, P. Fenaux, M. Vanrumbeke, 1997 .

NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents

C. Preudhomme, P. Fenaux, T. Cluzeau, 2018, Haematologica.

[p53 and hematologic malignancies].

C. Preudhomme, P. Fenaux, 1997, Pathologie-biologie.

Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes.

E. Macintyre, C. Preudhomme, P. Fenaux, 2002, Blood.

MDS and AML with 17p deletion are associated to specific dysgranulopoiesis and a high incidence of p53 mutations

E. Wattel, C. Preudhomme, P. Fenaux, 1994 .

Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion

F. Sigaux, J. Cayuela, H. Dombret, 2015, The Journal of Immunology.

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia

B. Quesnel, C. Preudhomme, C. Berthon, 2020, Leukemia.

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

J. Cayuela, A. Vekhoff, P. Cony-Makhoul, 2021, Leukemia.

Glutathione S transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens

C. Preudhomme, P. Fenaux, M. Vanrumbeke, 1997, Leukemia.

The molecular anatomy of the FIP1L1-PDGFRA fusion gene

R. Yeh, M. Baccarani, G. Martinelli, 2009, Leukemia.

Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial

A. Baruchel, G. Leverger, C. Preudhomme, 2017, Pediatric hematology and oncology.

Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience

B. Quesnel, I. Yakoub-Agha, C. Preudhomme, 2021, Blood advances.

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

H. Dombret, D. Olive, S. Leprêtre, 2017 .

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia

B. Quesnel, A. Duhamel, C. Preudhomme, 2016, Oncotarget.

BCOR and BCORL 1 mutations in myelodysplastic syndromes and related disorders

D. Birnbaum, S. Miyano, Y. Shiraishi, 2013 .

Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21)

O. Abdel-Wahab, H. Dombret, G. Leverger, 2016, Leukemia & lymphoma.

Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group

A. Baruchel, G. Leverger, C. Preudhomme, 2023, Leukemia.

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

J. Soulier, E. Clappier, H. Dombret, 2023, Leukemia.

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

H. Dombret, C. Preudhomme, S. de Botton, 2023, Blood advances.

Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group

H. Dombret, C. Preudhomme, T. Cluzeau, 2022, Blood.

C. Preudhomme, F. Guilhot, N. Sorel, 2005, Leukemia & lymphoma.

Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL

I. Yakoub-Agha, C. Preudhomme, A. Decouvelaere, 2003, Leukemia.

Prognostic Significance of NOTCH1 and FBXW7 Mutations in Childhood T-Cell Acute Lymphoblastic Leukemia (T-ALL): Results From the EORTC Children Leukemia Group.

F. Speleman, E. Clappier, H. Cavé, 2009 .

First Overall Molecular Response of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

C. Preudhomme, F. Mahon, F. Guilhot, 2006 .

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes.

C. Preudhomme, P. Fenaux, L. Adès, 2015, Leukemia research.

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

C. Preudhomme, P. Fenaux, S. Thépot, 2022, Blood.

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

J. Cayuela, H. Dombret, M. Béné, 2011 .

Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells

C. Preudhomme, P. Fenaux, T. Facon, 1998, Leukemia.

Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia

C. Preudhomme, C. Roche-Lestienne, N. Grardel, 2015, Clinical case reports.

Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Lara E. Sucheston-Campbell, C. Gieger, A. Skol, 2022, Nature communications.

Targeting Aberrant Expression of CD81 Impacts Cell Adhesion and Migration, Drug Resistance and Prognosis of Acute Myeloid Leukemia

C. Preudhomme, C. Berthon, C. Roumier, 2017 .

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

M. Stratton, F. Artiguenave, L. Alexandrov, 2016, Nature Communications.

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

B. Quesnel, C. Preudhomme, P. Fenaux, 2014 .

Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib

C. Preudhomme, T. Facon, J. Laï, 2008 .

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

P. Vyas, N. Potter, A. Baruchel, 2019, Blood.

Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).

J. Soulier, J. Cayuela, H. Dombret, 2009 .

Results of the “Evaluation of NGS in AML-Diagnostics (ELAN)” Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories

C. Eberlein, L. Bullinger, K. Döhner, 2014 .

ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis

O. Abdel-Wahab, C. Preudhomme, A. Pastore, 2015 .

Genome Wide SNP Analysis Reveals Frequent Cryptic Clonal Chromosomal Aberrations Including Uniparental Disomy (UPD) in Waldenstrom's Macroglobulinemia.

C. Preudhomme, P. Morel, X. Leleu, 2009 .

Negative Impact of TET2 Mutations on Long-Term Survival After Transcatheter Aortic Valve Replacement

D. Dombrowicz, S. Susen, C. Preudhomme, 2023, JACC. Basic to translational science.

Homozygous G20210A Transition in the Prothrombin Gene Associated with Severe Venous Thrombotic Disease: Two Cases in a French Family

B. Jude, C. Preudhomme, C. Zawadzki, 1998, Thrombosis and Haemostasis.

C/EBPA methylation is common in T-ALL but not in M0 AML.

H. Dombret, G. Leverger, E. Macintyre, 2009, Blood.

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).

J. Cayuela, C. Preudhomme, S. de Botton, 2002, Blood.

Correction: Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Dede Sika Kossi, On behalf of NGSEco Group, I. Durand-zaleski, 2018, European Journal of Human Genetics.

C. Lorthois, C. Preudhomme, P. Fenaux, 1991, Leukemia & lymphoma.

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).

J. Cayuela, C. Preudhomme, S. de Botton, 2002, Blood.

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

C. Preudhomme, I. Tigaud, J. Laï, 2007, Blood.

The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.

H. Dombret, C. Preudhomme, C. Gardin, 2009, Blood.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

H. Dombret, E. Solary, O. Bernard, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

O. Abdel-Wahab, H. Dombret, G. Leverger, 2014, Blood.

Clonal architecture of chronic myelomonocytic leukemias.

E. Solary, W. Vainchenker, O. Bernard, 2013, Blood.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

D. Birnbaum, T. Haferlach, E. Solary, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Martin C. Müller, I. Dufva, G. Martinelli, 2009, Blood.

behavior of blastic plasmacytoid

Marc C. Jacob, F. Jardin, B. Drénou, 2021 .

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

H. Dombret, S. Chevret, C. Preudhomme, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations

H. Dombret, C. Preudhomme, M. Cheok, 2015, American journal of hematology.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

O. Abdel-Wahab, H. Dombret, G. Leverger, 2016, Blood.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

H. Dombret, C. Preudhomme, R. Benner, 2018, Haematologica.

Mutation Status of Imatinib Mesylate-Resistants CML Patients and Clinical Outcomes: A French Multicenter Retrospective Study for the fiLMC Group.

C. Preudhomme, S. Hayette, G. Marit, 2004 .

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Lionel Perrier, Isabelle Durand-Zaleski, Rajae Touzani, 2018, European Journal of Human Genetics.

A case of refractory anemia with 17p− syndrome following azathioprine treatment for heart transplantation

B. Quesnel, C. Preudhomme, S. Depil, 2004, Leukemia.

Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

C. Preudhomme, P. Rousselot, F. Mahon, 2013, Cancer.

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2017, Clinical Cancer Research.

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up.

B. Quesnel, A. Plesa, C. Preudhomme, 2018, Journal of visualized experiments : JoVE.

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

B. Quesnel, E. Leprêtre, E. Bertrand, 2015, Clinical Cancer Research.

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2013, American journal of hematology.

Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9‐dependent AML

C. Preudhomme, M. Bouhlel, M. Figeac, 2024, HemaSphere.

Tetraspanin CD81 promotes leukemia stem cell function and represents a new therapeutic vulnerability in acute myeloid leukemia

A. Plesa, C. Preudhomme, C. Berthon, 2023, bioRxiv.

Absence of CALR mutations in JAK2-negative polycythemia

C. Preudhomme, V. Ugo, E. Lippert, 2017, Haematologica.

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study

C. Preudhomme, R. Itzykson, C. Terré, 2024, Blood cancer journal.

Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts‐de‐France AML observatory

B. Quesnel, C. Preudhomme, C. Berthon, 2018, American journal of hematology.

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.

A. Stamatoullas, E. Solary, S. Chevret, 2016, Blood.

Neurofibromatosis‐1 gene deletions and mutations in de novo adult acute myeloid leukemia

J. Soulier, H. Dombret, C. Preudhomme, 2013, American journal of hematology.

Correlation of Clonal Hematopoiesis in Vexas Syndrome with Immunophenotype Alterations in CD34+ HSPCs (Hematopoietic Stem Progenitors Cells): Multiparametric Flow Cytometry Heterogeneity in CD34+CD38- Stem Cells Fraction and Upregulation of CD90 Thy-1 By Unsupervised Strategy Using PCA, Tsnee and Fl

A. Plesa, C. Preudhomme, S. Hayette, 2022, Blood.

Acute myeloblastic leukemia (AML) with inv (16)(p13;q22) and the rare I type CBFbeta-MYH11 transcript: report of two new cases.

C. Preudhomme, P. Fenaux, C. Roumier, 2002, Leukemia.

Prognostic Significance of SALL4 Expression Levels in Paediatric Acute Myeloid Leukaemia (AML).

J. Zucman‐Rossi, C. Deswarte, G. Leverger, 2008 .

Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

S. Fröhling, M. Cazzola, J. Klco, 2023, Blood advances.